Functional networks impairment along the process of AD: prediction value and resilience factors
Register to watch this free webinar on-demand. A link to watch the recording will then be emailed to you shortly after registration.
Fernando Maestú discusses a series of studies, which mainly used MEG to record the resting-state activity and a memory task in patients with Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), and in healthy subjects at preclinical stage or at risk for developing dementia. All these findings together indicate that hyper synchronization of the brain networks could be an excellent non-invasive biomarker for tracking the disease and evaluate interventions.
1. Brief introduction to the history of MEG in Alzheimer s Disease
2. Why MEG?
3. MEG clinical studies in early stages of AD (MCI and SCD)
4. MEG profiles of MCI converters versus non-converters
5. MEG profiles in combination with amyloid, tau and APOE4
6. Is there a chance for improving the brain network? Physical activity, cognitive training and
diet as a potential non-pharmacological intervention
7. How these MEG profiles are in association of findings found in animal models and
computational neuroscience studies.
Fernando Maestú Bio:
Full professor in experimental psychology, complutense University of Madrid
Director of the Laboratory of Cognitive and Computational Neuroscience in the Center of Biomedical Technology
Staff Scientist at University of Texas Houston
A joining link to watch the MEGIN Masterclass will then be emailed to you shortly after registration.
*MEGIN does not endorse any applications or treatments mentioned at this event. TRIUX™ neo is intended to non-invasively locate regions of epileptic activity within the brain and, in conjunction with other diagnostic data, in neurosurgical planning. All other applications are research in nature.
*By submitting your information to register for a Masterclass, MEGIN will use it to communicate with you regarding this event and other services.